These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 10631617)

  • 1. "Clinical pharmacology studies in patients with renal impairment: past experience and regulatory perspectives".
    Swan S; Elliott WJ; Bakris G
    J Clin Pharmacol; 2000 Jan; 40(1):7-10. PubMed ID: 10631617
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical pharmacology studies in patients with renal impairment: past experience and regulatory perspectives.
    Ibrahim S; Honig P; Huang SM; Gillespie W; Lesko LJ; Williams RL
    J Clin Pharmacol; 2000 Jan; 40(1):31-8. PubMed ID: 10631619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Guidelines for the clinical evaluation of antianxiety drugs. HEW (FDA) 77-3043, September 1977.
    Methods Find Exp Clin Pharmacol; 1979 Dec; 1(5):297-312. PubMed ID: 45205
    [No Abstract]   [Full Text] [Related]  

  • 4. Individualization of drug dosage in patients with renal disease.
    Dettli L
    Med Clin North Am; 1974 Sep; 58(5):977-85. PubMed ID: 4425338
    [No Abstract]   [Full Text] [Related]  

  • 5. Regulatory perspectives on designing pharmacokinetic studies and optimizing labeling recommendations for patients with chronic kidney disease.
    Zhang L; Xu N; Xiao S; Arya V; Zhao P; Lesko LJ; Huang SM
    J Clin Pharmacol; 2012 Jan; 52(1 Suppl):79S-90S. PubMed ID: 22232757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nephro-pharmacology.
    Keller F; Ludwig U; Czock D
    Int J Clin Pharmacol Ther; 2006 Aug; 44(8):343. PubMed ID: 16961164
    [No Abstract]   [Full Text] [Related]  

  • 7. Social, cultural and ethical aspects of drug use -- changes over 40 years: a personal look back.
    Herxheimer A; Sanz E
    Eur J Clin Pharmacol; 2008 Feb; 64(2):107-14. PubMed ID: 18172625
    [No Abstract]   [Full Text] [Related]  

  • 8. A set of simple aids to drug dosage adjustment in renal insufficiency.
    Janků I; Modr Z; Krebs V
    Int J Clin Pharmacol Ther Toxicol; 1990 Jan; 28(1):27-32. PubMed ID: 2303310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. American College of Clinical Pharmacology position statement on the use of microdosing in the drug development process.
    Bertino JS; Greenberg HE; Reed MD;
    J Clin Pharmacol; 2007 Apr; 47(4):418-22. PubMed ID: 17389550
    [No Abstract]   [Full Text] [Related]  

  • 10. Statistical analyses of adverse event data from clinical trials. Special emphasis on serious events.
    O'Neill RT
    Drug Inf J; 1987; 21(1):9-20. PubMed ID: 10281640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Doses Evaluated in Clinical Pharmacology Studies Investigating the Effect of Intrinsic and Extrinsic Factors on PK and Safety: Case Examples from Approved Drug Development Programs.
    Kaspera R; Shitara Y
    AAPS J; 2024 Jun; 26(4):71. PubMed ID: 38886275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simple approach to dosage adjustment in patients with renal impairment.
    McCormack JP; Cooper J; Carleton B
    Am J Health Syst Pharm; 1997 Nov; 54(21):2505-9. PubMed ID: 9359960
    [No Abstract]   [Full Text] [Related]  

  • 13. Developmental pharmacology: past, present and future.
    Blumer JL
    Acta Paediatr Jpn; 1996 Dec; 38(6):555-61. PubMed ID: 9002286
    [No Abstract]   [Full Text] [Related]  

  • 14. Modeling and predicting drug pharmacokinetics in patients with renal impairment.
    Rowland Yeo K; Aarabi M; Jamei M; Rostami-Hodjegan A
    Expert Rev Clin Pharmacol; 2011 Mar; 4(2):261-74. PubMed ID: 22115405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The current state of knowledge on age, sex, and their interactions on clinical pharmacology.
    Schwartz JB
    Clin Pharmacol Ther; 2007 Jul; 82(1):87-96. PubMed ID: 17495875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drugs and the Kidneys: Clinical Pharmacology Perspectives.
    Vincent J
    Clin Pharmacol Ther; 2017 Sep; 102(3):368-372. PubMed ID: 28782823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [How to improve drug development and utilization in pediatrics].
    Pons G; Lassale C; Eschwege E
    Therapie; 1999; 54(4):423-32. PubMed ID: 10667109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Background incidence of serum creatinine threshold rises in a predominantly female clinical trial population without underlying renal disease.
    Liu Y; Hunt C; Bains C; Weil JG
    Regul Toxicol Pharmacol; 2010 Nov; 58(2):297-300. PubMed ID: 20600452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Commentary on ACCP position statement on the use of microdosing in the drug development process.
    Rowland M
    J Clin Pharmacol; 2007 Dec; 47(12):1595-6; author reply 1597-8. PubMed ID: 18048576
    [No Abstract]   [Full Text] [Related]  

  • 20. Toxicology evaluation and single intravenous dose studies in human subjects.
    Colburn WA
    J Clin Pharmacol; 1997 Jan; 37(1):4-6. PubMed ID: 9048266
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.